QL Biopharm

Executive Summary

QL Biopharm is a preclinical-stage oncology biotech developing multispecific antibody therapeutics designed to engage multiple cancer targets simultaneously, aiming to enhance tumor killing and overcome resistance. Founded in 2020 and headquartered in San Diego, the company has raised $72.9 million to advance its lead programs toward clinical trials for solid tumors and hematologic malignancies. Its novel approach targets key challenges in oncology, such as tumor heterogeneity and acquired resistance, positioning it as a potential next-generation immunotherapy player. While still in preclinical development, the company's strong funding and innovative platform suggest promising prospects, though clinical validation is pending.

Upcoming Catalysts (preview)

• Q4 2026IND submission for lead multispecific antibody program70% success
• Q1 2027Initiation of first-in-human Phase 1 trial60% success
• Q3 2026Presentation of preclinical proof-of-concept data at major conference80% success